Lanean...
Drug Development and Potential Regulatory Paths for Insulin Biosimilars
Under the Biologics Price Competition and Innovation Act (BPCI Act), a biological product may be demonstrated to be “biosimilar” if data show that, among other things, the product is “highly similar” to an already-approved biological product. Biosimilar insulins have the potential to reduce ever gro...
Gorde:
| Argitaratua izan da: | J Diabetes Sci Technol |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
SAGE Publications
2014
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4454099/ https://ncbi.nlm.nih.gov/pubmed/24876531 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296813516954 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|